Showing results (1871-1880 of 2,317) with videos related to

Sort By:
Pageof 232
Cancer Letters|December 14, 2018
Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytesNai-Yun Sun, Yu-Li Chen, Han-Wei Lin, et al.
International Journal of Biological Sciences|February 5, 2020
Empagliflozin Attenuates Hyperuricemia by Upregulation of ABCG2 via AMPK/AKT/CREB Signaling Pathway in Type 2 Diabetic MiceYun-Hong Lu, Yun-Peng Chang, Ting Li, et al.
International Journal of Clinical Pharmacology and Therapeutics|October 5, 2022
Research progress in targeted therapies for gastric cancerMin Ye, Li-Juan Xiu, Qing-Qing Ji, et al.
Plos One|June 7, 2019
Reinforcement of patient education improved physicians' adherence to guideline-recommended medical therapy after acute coronary syndromeChih-Kuo Lee, Chao-Lun Lai, Ming-Hsien Lee, et al.
Cancer Management and Research|March 14, 2022
Integrated Bioinformatics Analysis and Validation of the Prognostic Value of <i>RBM10</i> Expression in Hepatocellular CarcinomaShu-Jie Pang, Zhe Sun, Wen-Feng Lu, et al.
Frontiers in Public Health|April 5, 2021
Association Between Aspirin Use and Decreased Risk of Pneumonia in Patients With Cardio-Cerebra-Vascular Ischemic Disease: A Population-Based Cohort StudyYing-Cheng Chen, Yin-Yang Chen, Han Wei Yeh, et al.
Analytical Chemistry|January 29, 2015
MAGIC: an automated N-linked glycoprotein identification tool using a Y1-ion pattern matching algorithm and in silico MS² approachKe-Shiuan Lynn, Chen-Chun Chen, T Mamie Lih, et al.
British Journal of Cancer|May 19, 2021
Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 studyYing Cheng, Qiming Wang, Kai Li, et al.
Cancer Medicine|September 15, 2021
Increased risk of second primary malignancies among endometrial cancer survivors receiving surgery alone: A population-based analysisYen-Ling Lai, Chun-Ju Chiang, Yu-Li Chen, et al.
International Immunopharmacology|February 13, 2024
Scleroglucan protects the intestine from irradiation-induced injury by targeting the IL-17 signaling pathwayDaqian Huang, Yuedong Wang, Xuanlu Zhai, et al.
Pageof 232